U.S. Markets closed
  • S&P 500

    4,538.43
    -38.67 (-0.84%)
     
  • Dow 30

    34,580.08
    -59.71 (-0.17%)
     
  • Nasdaq

    15,085.47
    -295.85 (-1.92%)
     
  • Russell 2000

    2,159.31
    -47.02 (-2.13%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    48,955.22
    -4,906.50 (-9.11%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

ORMP: Multiple Opportunities Advance; Senior Team Expands to Support Growth

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By M. Marin

NASDAQ:ORMP

READ THE FULL ORMP RESEARCH REPORT

Enrollments in T2D Concurrent Dual Studies Continue to Advance …

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced this week that it has enrolled and randomized more than 25% of the planned 450 patients for the Phase 3 ORA-D-013-2 trial of ORMD-0801 for the treatment of type 2 diabetes (T2D). The company had earlier announced that it has enrolled and randomized about 50% of the 675 patients planned in the Phase 3 ORA-D-013-1 study of ORMD-0801. This dual study represents the world's first pivotal Phase 3 oral insulin trial conducted through an FDA approved protocol, underscoring Oramed's position as a pioneer in the study for oral insulin.

… while JV moves oral COVID vaccine forward - testing for variants …

In addition to focusing on pursuing opportunities in its core diabetes space, ORMP has also entered the COVID-19 vaccine space through a recently formed joint venture, Oravax Medical Inc., to advance an orally administered vaccine for the COVID-19 virus. The Oravax vaccine represents a successful expansion of Oramed's POD™ oral protein delivery platform into the vaccine development market.

The vaccine currently is being tested against COVID-19 variants, including the Delta variant. Oravax intends to launch clinical trials for the oral COVID-19 vaccine, beginning in Israel, with additional international locations to follow. The many potential competitive advantage of a vaccine in pill form is easier and less expensive distribution and storage and the potential to overcome vaccine hesitancy.

… and other assets / studies, including NASH study and ORMD-0901 technology platform, represent additional opportunities

As the company’s opportunities have multiplied, ORMP has also expanded its senior management team to help facilitate the development and expected commercialization of its growing asset portfolio. Oramed appointed industry veteran Michael Rabinowitz to the newly created position of Chief Commercial Officer effective August 1, 2021. He is responsible for Oramed's overall commercial strategy and execution.

Separately, ORMP shares were recently included in the U.S. small cap Russell 2000® and broad-market Russell 3000® Index following the Russell annual reconstitution. We believe the addition to the Russell indices boosts awareness of the company and its growing prospects within the investment community and increases the pool of potential investors who can acquire ORMP shares, as the company continues to execute its growth strategy.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.